These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2910775)

  • 1. In vitro sensitivity of ovarian cancer as determined by a short-term biochemical assay: comparison between primary and metastatic sites in the same patient.
    Khoo SK; Hurst T; Lark J; Webb MJ; Parsons P; Mackay EV
    Gynecol Oncol; 1989 Feb; 32(2):151-5. PubMed ID: 2910775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of drug resistance in human breast and ovarian cancers.
    Kern DH
    Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro chemotherapy sensitivity testing of human ovarian carcinoma: comparison of optical colony counting and [3H]thymidine incorporation assays.
    Tsushima K; Podratz KC; Stanhope CR; Lieber MM
    Gynecol Oncol; 1987 Oct; 28(2):170-80. PubMed ID: 3666575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas.
    Hayward IP; Hurst T; Parsons PG; Khoo SK
    Int J Cell Cloning; 1992 May; 10(3):182-9. PubMed ID: 1613269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
    Tewari KS; Mehta RS; Burger RA; Yu IR; Kyshtoobayeva AS; Monk BJ; Manetta A; Berman ML; Disaia PJ; Fruehauf JP
    Gynecol Oncol; 2005 Sep; 98(3):360-8. PubMed ID: 16000215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitivity testing of ovarian cancer: results of a rapid in vitro biochemical assay.
    Khoo SK; Hurst T; Webb MJ
    Aust N Z J Obstet Gynaecol; 1985 Aug; 25(3):215-20. PubMed ID: 3866561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of in vitro drug sensitivity testing based on short-term effects on DNA and RNA metabolism in ovarian cancer.
    Khoo SK; Hurst T; Webb MJ; Dickie G; Kearsley J; Parsons PG; Mackay EV
    J Surg Oncol; 1989 Jul; 41(3):201-5. PubMed ID: 2747246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin chemotherapy of ovarian cancer: is short-term in vitro chemosensitivity predictive of long-term patient survival?
    Khoo SK; Hurst T; Webb MJ; Dickie G; Kearsley J; Parsons PG; Mackay EV
    Aust N Z J Obstet Gynaecol; 1988 Nov; 28(4):313-7. PubMed ID: 3250450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of combination chemotherapy of ovarian cancer in vitro].
    Lu SM
    Zhonghua Yi Xue Za Zhi; 1992 Oct; 72(10):590-2, 638. PubMed ID: 1284340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitivity testing of an ovarian cancer cell line: comparison of MTT assay and [3H]-thymidine incorporation.
    Yu KJ; Ng HT; Chao KC; Chang CC; Kan YY
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Feb; 47(2):79-85. PubMed ID: 1848139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cell proliferation and cell death based assays in chemosensitivity testing.
    Gerçel-Taylor C; Ackermann MA; Taylor DD
    Anticancer Res; 2001; 21(4A):2761-8. PubMed ID: 11724352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
    Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR
    Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer.
    Silvestrini R; Zaffaroni N; Orlandi L; Oriana S
    Stem Cells; 1993 Nov; 11(6):528-35. PubMed ID: 7906583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
    Nakada S; Aoki D; Ohie S; Horiuchi M; Suzuki N; Kanasugi M; Susumu N; Udagawa Y; Nozawa S
    Int J Gynecol Cancer; 2005; 15(3):445-52. PubMed ID: 15882168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug sensitivity of different tumor lesions from the same patient evaluated by a short-term assay.
    Zaffaroni N; Silvestrini R; Sanfilippo O; Daidone MG; Bolis G; Seminara P
    Tumori; 1988 Apr; 74(2):137-44. PubMed ID: 3368967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro drug-resistance decrease of ovarian cancer cells].
    Lu SM
    Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):348-51, 383. PubMed ID: 2282862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.